UNSPSC 51101692: Tivanidazole

This classification denotes an antiprotozoal agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7E136TJT00. European Medicines Agency schedules Tivanidazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11123MIG. Tivanidazole generally arises in the molecular formula C11H13N5O2S.

UNSPSC 51101692 Tivanidazole is a Commodity code that nominally specifies a single antiprotozoal pharmaceutical, but recent state and local solicitations show minimal direct procurement activity under this specific drug identifier. Instead, state and local governments issuing opportunities tagged to this code are actually procuring broader pharmaceutical and medical supply categories—generic multi-source pharmaceuticals, over-the-counter products, naloxone, emergency medical supplies, and therapeutic pharmacy services. The mismatch between the code's narrow drug specification and the actual scope of work being solicited suggests either administrative classification variance or that tivanidazole represents a commodity within larger pharmaceutical purchasing frameworks rather than a standalone procurement target. Issuing bodies across these opportunities include state health and human services agencies (Texas HHS Commission, Minnesota Department of Administration), county health systems (Seminole County, Florida), and municipal fire and rescue departments (City of Tampa). The procurement mechanisms span RFPs for cooperative purchasing (Minnesota MMCAP), RFIs for direct-to-manufacturer pharmacy programs, IBFs for emergency medical supplies, and IFBs for drug deactivation systems and naloxone kits.

Recent activity concentrates in Florida, Texas, and Minnesota. Representative solicitations include Seminole County's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems with a response deadline of July 26, 2023 (notice posted June 30, 2026); the City of Tampa's IFB for 169 line items of medical and first aid supplies for the Tampa Fire Department Rescue Division, posted March 25, 2026 with an estimated contract value of $700,000 and a response deadline of March 13, 2026; and the Minnesota MMCAP RFP for generic multi-source pharmaceuticals and OTC products, posted January 20, 2026 with a response deadline of March 26, 2026. The Texas HHS Commission issued an RFI in April 2026 to explore direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and wholesaler channels, signaling longer-term strategic procurement interest in alternative pharmaceutical supply models. The Tampa procurement carries an SLBE set-aside with a 5 percent bid discount, while the Minnesota MMCAP opportunity emphasizes price competitiveness (75 percent of evaluation weight) and requires vendor relationships with specific authorized wholesalers.